...
search icon
galt-img

Galectin Therapeutics Inc, Common Stock

GALT

NAQ

$1.28

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$83.54M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
108.41K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.63
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.73 L
$3.17 H
$1.28

About Galectin Therapeutics Inc, Common Stock

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGALTSectorS&P500
1-Week Return-3.03%0.86%-1.29%
1-Month Return-3.76%-2.58%10.63%
3-Month Return-12.33%-10.87%-2.43%
6-Month Return-53.96%-8.73%-2.14%
1-Year Return-58.84%-10.19%10%
3-Year Return-3.03%0.5%46.86%
5-Year Return-59.37%32.08%97.3%
10-Year Return-53.45%75.49%174.39%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue36.00K41.00K32.00K33.00K37.00K[{"date":"2020-12-31","value":87.8,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.05,"profit":true},{"date":"2023-12-31","value":80.49,"profit":true},{"date":"2024-12-31","value":90.24,"profit":true}]
Gross Profit(36.00K)(41.00K)(32.00K)(33.00K)-[{"date":"2020-12-31","value":-3600000,"profit":false},{"date":"2021-12-31","value":-4100000,"profit":false},{"date":"2022-12-31","value":-3200000,"profit":false},{"date":"2023-12-31","value":-3300000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses23.44M30.18M38.35M38.04M42.43M[{"date":"2020-12-31","value":55.25,"profit":true},{"date":"2021-12-31","value":71.12,"profit":true},{"date":"2022-12-31","value":90.38,"profit":true},{"date":"2023-12-31","value":89.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(23.44M)(30.18M)(38.35M)(38.07M)(42.43M)[{"date":"2020-12-31","value":-2344400000,"profit":false},{"date":"2021-12-31","value":-3017900000,"profit":false},{"date":"2022-12-31","value":-3835200000,"profit":false},{"date":"2023-12-31","value":-3807200000,"profit":false},{"date":"2024-12-31","value":-4243300000,"profit":false}]
Total Non-Operating Income/Expense(42.00K)(834.00K)(1.41M)(5.06M)(9.82M)[{"date":"2020-12-31","value":-4200000,"profit":false},{"date":"2021-12-31","value":-83400000,"profit":false},{"date":"2022-12-31","value":-140500000,"profit":false},{"date":"2023-12-31","value":-506100000,"profit":false},{"date":"2024-12-31","value":-981600000,"profit":false}]
Pre-Tax Income(23.46M)(30.53M)(38.78M)(41.07M)(47.05M)[{"date":"2020-12-31","value":-2346500000,"profit":false},{"date":"2021-12-31","value":-3052700000,"profit":false},{"date":"2022-12-31","value":-3877600000,"profit":false},{"date":"2023-12-31","value":-4106600000,"profit":false},{"date":"2024-12-31","value":-4704700000,"profit":false}]
Income Taxes51.00K448.00K424.00K(2.99M)-[{"date":"2020-12-31","value":11.38,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.64,"profit":true},{"date":"2023-12-31","value":-668.3,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(23.52M)(30.98M)(39.20M)(38.07M)-[{"date":"2020-12-31","value":-2351600000,"profit":false},{"date":"2021-12-31","value":-3097500000,"profit":false},{"date":"2022-12-31","value":-3920000000,"profit":false},{"date":"2023-12-31","value":-3807200000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(23.46M)(30.53M)(38.78M)(41.70M)(47.05M)[{"date":"2020-12-31","value":-2346500000,"profit":false},{"date":"2021-12-31","value":-3052700000,"profit":false},{"date":"2022-12-31","value":-3877600000,"profit":false},{"date":"2023-12-31","value":-4170300000,"profit":false},{"date":"2024-12-31","value":-4704700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(23.46M)(30.53M)(38.78M)(41.07M)(47.05M)[{"date":"2020-12-31","value":-2346500000,"profit":false},{"date":"2021-12-31","value":-3052700000,"profit":false},{"date":"2022-12-31","value":-3877600000,"profit":false},{"date":"2023-12-31","value":-4106600000,"profit":false},{"date":"2024-12-31","value":-4704700000,"profit":false}]
EPS (Diluted)(0.40)(0.51)(0.65)(0.74)(0.76)[{"date":"2020-12-31","value":-40,"profit":false},{"date":"2021-12-31","value":-51,"profit":false},{"date":"2022-12-31","value":-65,"profit":false},{"date":"2023-12-31","value":-74,"profit":false},{"date":"2024-12-31","value":-76,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GALT
Cash Ratio 0.07
Current Ratio 0.08

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GALT
ROA (LTM) -143.58%
ROE (LTM) -3727.95%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GALT
Debt Ratio Lower is generally better. Negative is bad. 12.78
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -11.96

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GALT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 207.70
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Galectin Therapeutics Inc share price today?

Galectin Therapeutics Inc (GALT) share price today is $1.28

Can Indians buy Galectin Therapeutics Inc shares?

Yes, Indians can buy shares of Galectin Therapeutics Inc (GALT) on Vested. To buy Galectin Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GALT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Galectin Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Galectin Therapeutics Inc (GALT) via the Vested app. You can start investing in Galectin Therapeutics Inc (GALT) with a minimum investment of $1.

How to invest in Galectin Therapeutics Inc shares from India?

You can invest in shares of Galectin Therapeutics Inc (GALT) via Vested in three simple steps:

  • Click on Sign Up or Invest in GALT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Galectin Therapeutics Inc shares
What is Galectin Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Galectin Therapeutics Inc (GALT) is $3.17. The 52-week low price of Galectin Therapeutics Inc (GALT) is $0.73.

What is Galectin Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Galectin Therapeutics Inc (GALT) is 207.70

What is the Market Cap of Galectin Therapeutics Inc?

The market capitalization of Galectin Therapeutics Inc (GALT) is $83.54M

What is Galectin Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Galectin Therapeutics Inc is GALT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top